Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.

about

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.

Item

http://www.wikidata.org/entity/Q55359395

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Combined alkylation and histon ...... tumors in preclinical models.

@en

Combined alkylation and histon ...... tumors in preclinical models.

@nl

type

Item

label

Combined alkylation and histon ...... tumors in preclinical models.

@en

Combined alkylation and histon ...... tumors in preclinical models.

@nl

prefLabel

Combined alkylation and histon ...... tumors in preclinical models.

@en

Combined alkylation and histon ...... tumors in preclinical models.

@nl

P1476

Combined alkylation and histon ...... n tumors in preclinical models

@en

P2093

Han W Tun

http://www.w3.org/2001/XMLSchema#string

John A Copland

http://www.w3.org/2001/XMLSchema#string

Thomas Mehrling

http://www.w3.org/2001/XMLSchema#string

Yushi Qiu

http://www.w3.org/2001/XMLSchema#string

Zhimin Li

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

P304

28155-28164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25588

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29963268

http://www.w3.org/2001/XMLSchema#string

P932

6021334

http://www.w3.org/2001/XMLSchema#string